P.0672 Zuranolone 30 mg in major depressive disorder: results through 1-year follow-up from the Phase 3, open-label, SHORELINE study

Autor:	A. Cutler, S. Aaronson, G. Mattingly, S. Wilkinson, R. Lasser, I. Nandy, B. Werneburg, J. Jonas, S. Kanes
Rok vydání:	2021
Předmět:	Pharmacology Psychiatry and Mental health Neurology Pharmacology (medical) Neurology (clinical) Biological Psychiatry
Zdroj:	European Neuropsychopharmacology. 53:S492-S493
ISSN:	0924-977X
DOI:	10.1016/j.euroneuro.2021.10.634
Databáze:	OpenAIRE
Externí odkaz:	https://explore.openaire.eu/search/publication?articleId=doi_________::1f903e1d70d529607e31952fe016beb8 https://doi.org/10.1016/j.euroneuro.2021.10.634 Zobrazit plný text záznamu Full Text from ScienceDirect